Positive results for Australian company testing peptide to target glaucoma Perth pharmaceutical company NeuroScientific Biopharmaceuticals (NSB) has announced its lead drug candidate slowed glaucoma-induced damage to the optic nerve, in findings that highlight its potential as a clinically useful treatment.Read More rhiannon bowmanMay 5, 2020, 3:03 pmMay 5, 2020